FR2849029B1 - Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. - Google Patents

Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.

Info

Publication number
FR2849029B1
FR2849029B1 FR0216412A FR0216412A FR2849029B1 FR 2849029 B1 FR2849029 B1 FR 2849029B1 FR 0216412 A FR0216412 A FR 0216412A FR 0216412 A FR0216412 A FR 0216412A FR 2849029 B1 FR2849029 B1 FR 2849029B1
Authority
FR
France
Prior art keywords
enantiomer
ray diffraction
diffraction pattern
interplanar spacings
maxima corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0216412A
Other languages
English (en)
French (fr)
Other versions
FR2849029A1 (fr
Inventor
Olivier Neckebrock
Laurent Courvoisier
Stephanie Graf
Gilles Serrure
Gerard Coquerel
Sebastien Rose
Christine Besselievre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Sante SAS
Original Assignee
Organisation de Synthese Mondiale Orsymonde SA
Laboratoire L Lafon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2849029(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organisation de Synthese Mondiale Orsymonde SA, Laboratoire L Lafon SA filed Critical Organisation de Synthese Mondiale Orsymonde SA
Priority to FR0216412A priority Critical patent/FR2849029B1/fr
Priority to CNB2003801098134A priority patent/CN100540533C/zh
Priority to US10/539,918 priority patent/US7132570B2/en
Priority to NZ571235A priority patent/NZ571235A/en
Priority to EA200501016A priority patent/EA009592B1/ru
Priority to BRPI0316916-2A priority patent/BRPI0316916B1/pt
Priority to EP13177661.9A priority patent/EP2676952A3/fr
Priority to AU2003299349A priority patent/AU2003299349C1/en
Priority to EP13177658.5A priority patent/EP2679577A3/fr
Priority to KR1020057011619A priority patent/KR101050565B1/ko
Priority to CN2010101503175A priority patent/CN101914044A/zh
Priority to MXPA05006525A priority patent/MXPA05006525A/es
Priority to JP2004564285A priority patent/JP4719471B2/ja
Priority to NZ540733A priority patent/NZ540733A/en
Priority to PL377196A priority patent/PL377196A1/pl
Priority to PCT/FR2003/003799 priority patent/WO2004060858A1/fr
Priority to DK11163602.3T priority patent/DK2343275T3/da
Priority to PT111636023T priority patent/PT2343275E/pt
Priority to CA2724305A priority patent/CA2724305A1/fr
Priority to ES13177660.1T priority patent/ES2575018T3/es
Priority to UAA200507106A priority patent/UA100964C2/ru
Priority to EP03799631.1A priority patent/EP1572635B1/fr
Priority to CN201610461501.9A priority patent/CN106065007A/zh
Priority to CN200910152177A priority patent/CN101654423A/zh
Priority to ES03799631.1T priority patent/ES2627808T3/es
Priority to CA2510096A priority patent/CA2510096C/fr
Priority to CN2007100017638A priority patent/CN101012189B/zh
Priority to EP13177660.1A priority patent/EP2679578B1/fr
Priority to EP11163602.3A priority patent/EP2343275B1/fr
Priority to EP13177648.6A priority patent/EP2679576A3/fr
Priority to ES11163602T priority patent/ES2425023T3/es
Priority to SI200332281T priority patent/SI2343275T1/sl
Priority to ARP030104730A priority patent/AR042546A1/es
Priority to MYPI20034935A priority patent/MY142926A/en
Priority to TW092136443A priority patent/TWI344952B/zh
Publication of FR2849029A1 publication Critical patent/FR2849029A1/fr
Application granted granted Critical
Publication of FR2849029B1 publication Critical patent/FR2849029B1/fr
Priority to ZA200504805A priority patent/ZA200504805B/en
Priority to NO20052912A priority patent/NO335724B1/no
Priority to IL169205A priority patent/IL169205A/en
Priority to EGNA2005000326 priority patent/EG24849A/xx
Priority to IS7947A priority patent/IS7947A/is
Priority to HK11112662.9A priority patent/HK1158171B/xx
Priority to US11/474,859 priority patent/US20060241320A1/en
Priority to CL2007002450A priority patent/CL2007002450A1/es
Priority to US12/507,584 priority patent/US9382200B2/en
Priority to US12/507,623 priority patent/US20090281193A1/en
Priority to US12/507,610 priority patent/US20100048719A1/en
Priority to US12/507,631 priority patent/US20100048720A1/en
Priority to US12/507,602 priority patent/US20100048718A1/en
Priority to US12/507,594 priority patent/US20090281192A1/en
Priority to AU2010212462A priority patent/AU2010212462A1/en
Priority to JP2011032155A priority patent/JP5497680B2/ja
Priority to US13/858,483 priority patent/US8729305B2/en
Priority to CY20131100573T priority patent/CY1114291T1/el
Priority to US14/012,363 priority patent/US8975442B2/en
Priority to HK14105599.8A priority patent/HK1192222B/xx
Priority to CL2016002640A priority patent/CL2016002640A1/es
Priority to HK16113750.5A priority patent/HK1225371A1/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0216412A 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. Expired - Fee Related FR2849029B1 (fr)

Priority Applications (57)

Application Number Priority Date Filing Date Title
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CNB2003801098134A CN100540533C (zh) 2002-12-20 2003-12-18 莫达非尼旋光对映异构体的晶形及其制备方法
US10/539,918 US7132570B2 (en) 2002-12-20 2003-12-18 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
NZ571235A NZ571235A (en) 2002-12-20 2003-12-18 Process for the preparation of optically active 2-benzhydrylsulfinylacetamide
EA200501016A EA009592B1 (ru) 2002-12-20 2003-12-18 Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила
BRPI0316916-2A BRPI0316916B1 (pt) 2002-12-20 2003-12-18 Processo para a preparação de formas cristalinas polimórficas de enantiômeros óticos levógiro de modafinila
EP13177661.9A EP2676952A3 (fr) 2002-12-20 2003-12-18 Procédé de préparation et formes cristallines IV des énantiomères optiques du modafinil
AU2003299349A AU2003299349C1 (en) 2002-12-20 2003-12-18 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
EP13177658.5A EP2679577A3 (fr) 2002-12-20 2003-12-18 Procédé de préparation de formes cristallines des énantiomeres optiques du modafinil et leur composition pharmaceutique
KR1020057011619A KR101050565B1 (ko) 2002-12-20 2003-12-18 모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법
CN2010101503175A CN101914044A (zh) 2002-12-20 2003-12-18 莫达非尼旋光对映异构体的晶形及其制备方法
MXPA05006525A MXPA05006525A (es) 2002-12-20 2003-12-18 Procedimiento de preparacion de formas cristalinas de enantiomeros opticos de modafinil.
JP2004564285A JP4719471B2 (ja) 2002-12-20 2003-12-18 モダフィニルの光学異性体の調製方法及び結晶形
NZ540733A NZ540733A (en) 2002-12-20 2003-12-18 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
PL377196A PL377196A1 (pl) 2002-12-20 2003-12-18 Sposób przygotowania i postacie krystaliczne enancjomerów optycznych modafinilu
PCT/FR2003/003799 WO2004060858A1 (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil
DK11163602.3T DK2343275T3 (da) 2002-12-20 2003-12-18 Krystallinsk form af optiske enantiomerer af modafinil
PT111636023T PT2343275E (pt) 2002-12-20 2003-12-18 Forma cristalina dos enantiómeros ópticos de modafinil
CA2724305A CA2724305A1 (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil
ES13177660.1T ES2575018T3 (es) 2002-12-20 2003-12-18 Forma cristalina de los enantiómeros ópticos de modafinilo
UAA200507106A UA100964C2 (ru) 2002-12-20 2003-12-18 Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила
EP03799631.1A EP1572635B1 (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil
CN201610461501.9A CN106065007A (zh) 2002-12-20 2003-12-18 莫达非尼旋光对映异构体的晶形及其制备方法
CN200910152177A CN101654423A (zh) 2002-12-20 2003-12-18 莫达非尼旋光对映异构体的晶形及其制备方法
ES03799631.1T ES2627808T3 (es) 2002-12-20 2003-12-18 Método para la producción de formas cristalinas y formas cristalinas de Enantiomeros ópticos de modafinil
CA2510096A CA2510096C (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil
CN2007100017638A CN101012189B (zh) 2002-12-20 2003-12-18 莫达非尼旋光对映异构体的晶形及其制备方法
EP13177660.1A EP2679578B1 (fr) 2002-12-20 2003-12-18 Procédé de préparation et une forme cristalline des énantiomères optiques du modafinil
EP11163602.3A EP2343275B1 (fr) 2002-12-20 2003-12-18 Forme cristalline des énantiomères optiques du modafinil.
EP13177648.6A EP2679576A3 (fr) 2002-12-20 2003-12-18 Procédé de préparation de formes cristallines des énantiomeres optiques du modafinil et leur composition pharmaceutique
ES11163602T ES2425023T3 (es) 2002-12-20 2003-12-18 Forma cristalina de los enantiómeros ópticos de modafinilo
SI200332281T SI2343275T1 (sl) 2002-12-20 2003-12-18 Kristaliniäśna oblika optiäśnih enantiomerov modafinila
ARP030104730A AR042546A1 (es) 2002-12-20 2003-12-19 Procedimiento de preparacion y formas cristalinas de los enantiomeros de modafinil, composiciones farmaceuticas y medicamentos que los contienen
MYPI20034935A MY142926A (en) 2002-12-20 2003-12-22 Method of the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
TW092136443A TWI344952B (en) 2002-12-20 2003-12-22 Process for the preparation of and crystalline forms of optical enantiomers of modafinil
ZA200504805A ZA200504805B (en) 2002-12-20 2005-06-13 Method for the procution of crystalline forms and crystalline forms of optical enantiomers of modafinil
NO20052912A NO335724B1 (no) 2002-12-20 2005-06-15 Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse
IL169205A IL169205A (en) 2002-12-20 2005-06-16 Polymorphically modulating abortifacient enantiomer, (i) form (i) of (-) - modafinil, pharmaceutical preparation and process for the preparation of (-) form (i) - modafinil polymorph
EGNA2005000326 EG24849A (en) 2002-12-20 2005-06-19 Method for the production of crystalline forms andcrystalline forms of optical enantiomers of modaf inil
IS7947A IS7947A (is) 2002-12-20 2005-07-19 Aðferð til að framleiða kristölluð form ljósfræðilegra handhverfa módafíníls
HK11112662.9A HK1158171B (en) 2002-12-20 2005-12-15 Crystalline form of the optical enantiomers of modafinil
US11/474,859 US20060241320A1 (en) 2002-12-20 2006-06-26 Process for the preparation of and crystalline forms of optical enantiomers of modafinil
CL2007002450A CL2007002450A1 (es) 2002-12-20 2007-08-22 Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
US12/507,584 US9382200B2 (en) 2002-12-20 2009-07-22 Process for the preparation of and crystalline forms of optical enantiomers of modafinil
US12/507,623 US20090281193A1 (en) 2002-12-20 2009-07-22 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
US12/507,610 US20100048719A1 (en) 2002-12-20 2009-07-22 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
US12/507,631 US20100048720A1 (en) 2002-12-20 2009-07-22 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
US12/507,602 US20100048718A1 (en) 2002-12-20 2009-07-22 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
US12/507,594 US20090281192A1 (en) 2002-12-20 2009-07-22 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
AU2010212462A AU2010212462A1 (en) 2002-12-20 2010-08-20 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
JP2011032155A JP5497680B2 (ja) 2002-12-20 2011-02-17 モダフィニルの異性体の調製方法及び結晶形
US13/858,483 US8729305B2 (en) 2002-12-20 2013-04-08 Process for the preparation of and crystalline forms of optical enantiomers of modafinil
CY20131100573T CY1114291T1 (el) 2002-12-20 2013-07-08 Κρυσταλλικη μορφη των οπτικων εναντιομερων της μοδαφινιλης
US14/012,363 US8975442B2 (en) 2002-12-20 2013-08-28 Process for the preparation of and crystalline forms of optical enantiomers of modafinil
HK14105599.8A HK1192222B (en) 2002-12-20 2014-06-13 Preparation method and crystalline form of optical enantiomers of modafinil
CL2016002640A CL2016002640A1 (es) 2002-12-20 2016-10-17 Procedimiento de preparación y formas cristalinas de los enantiómeros ópticos de modafinilo (divisional solicitud de origen 2693-2003).
HK16113750.5A HK1225371A1 (zh) 2002-12-20 2016-12-01 莫达非尼旋光对映异构体的晶形及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.

Publications (2)

Publication Number Publication Date
FR2849029A1 FR2849029A1 (fr) 2004-06-25
FR2849029B1 true FR2849029B1 (fr) 2005-03-18

Family

ID=32406320

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0216412A Expired - Fee Related FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.

Country Status (30)

Country Link
US (10) US7132570B2 (enExample)
EP (6) EP2343275B1 (enExample)
JP (2) JP4719471B2 (enExample)
KR (1) KR101050565B1 (enExample)
CN (5) CN101654423A (enExample)
AR (1) AR042546A1 (enExample)
AU (2) AU2003299349C1 (enExample)
BR (1) BRPI0316916B1 (enExample)
CA (2) CA2510096C (enExample)
CL (2) CL2007002450A1 (enExample)
CY (1) CY1114291T1 (enExample)
DK (1) DK2343275T3 (enExample)
EA (1) EA009592B1 (enExample)
EG (1) EG24849A (enExample)
ES (3) ES2575018T3 (enExample)
FR (1) FR2849029B1 (enExample)
HK (1) HK1225371A1 (enExample)
IL (1) IL169205A (enExample)
IS (1) IS7947A (enExample)
MX (1) MXPA05006525A (enExample)
MY (1) MY142926A (enExample)
NO (1) NO335724B1 (enExample)
NZ (2) NZ540733A (enExample)
PL (1) PL377196A1 (enExample)
PT (1) PT2343275E (enExample)
SI (1) SI2343275T1 (enExample)
TW (1) TWI344952B (enExample)
UA (1) UA100964C2 (enExample)
WO (1) WO2004060858A1 (enExample)
ZA (1) ZA200504805B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077894A1 (en) * 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7521553B2 (en) 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
DK1610796T3 (da) * 2003-03-17 2014-07-21 Neurohealing Pharmaceuticals Inc Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
MX2007012605A (es) * 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
CA2634133A1 (en) 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
WO2008021341A2 (en) * 2006-08-14 2008-02-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080214862A1 (en) * 2006-12-06 2008-09-04 Ben-Zion Dolitzky Processes for preparing armodafinil intermediate
US20100010092A1 (en) * 2006-12-19 2010-01-14 Arless Ltd. Use of modafinil to treat restless leg syndrome
US20100234468A1 (en) * 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
WO2009024863A2 (en) * 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
WO2009045488A2 (en) * 2007-10-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2292306B1 (en) 2009-09-02 2013-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
US20130085304A1 (en) * 2009-11-19 2013-04-04 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
CN102781446A (zh) * 2010-01-07 2012-11-14 维瓦斯公司 采用碳酸酐酶抑制剂和另外的活性剂的组合治疗阻塞性睡眠呼吸暂停综合征
EP2649187B1 (en) 2010-12-08 2017-11-22 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) * 2014-06-24 2019-11-05 Paypal, Inc. Surfacing related content based on user interaction with currently presented content
US10326922B2 (en) * 2014-07-23 2019-06-18 Orcam Technologies Ltd. Wearable apparatus and method for capturing image data using multiple image sensors
CN107000038A (zh) * 2014-11-27 2017-08-01 株式会社Gc 蜡模的表面处理剂以及制造牙科假体的方法
WO2017064723A1 (en) * 2015-10-12 2017-04-20 Natco Pharma Ltd An improved process for the preparation of armodafinil

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en) 1968-02-13 1970-07-08 Inst Noguchi Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr) 1988-02-10 1990-07-27 Lafon Labor 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2671349B1 (fr) 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CN1249932A (zh) 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US20010036640A1 (en) 2000-04-25 2001-11-01 D'amico Kevin L. System and methods for the high throughput screening of polymorphs
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
DE10025756C2 (de) * 2000-05-25 2003-02-20 Cognis Deutschland Gmbh Lösungsvermittler
WO2005077894A1 (en) 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
ES2277937T3 (es) * 2000-07-27 2007-08-01 Teva Pharmaceutical Industries Ltd. Modafinilo puro y cristalino y su procedimiento de preparacion.
US6835307B2 (en) * 2000-08-04 2004-12-28 Battelle Memorial Institute Thermal water treatment
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6919378B2 (en) 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
KR100704213B1 (ko) 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
US7297346B2 (en) 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
EP1466166B2 (en) 2002-01-15 2013-05-01 Avantium International B.V. Method for performing powder diffraction analysis
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
EP1525049B1 (en) 2002-08-02 2007-07-04 Avantium International B.V. An assembly and method for performing parallel chemical experiments, in particular crystallisation experiments
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
NZ545133A (en) 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
KR100872675B1 (ko) 2004-10-13 2008-12-10 파마시아 앤드 업존 캄파니 엘엘씨 3-[5-클로로-4-[(2,4-디플루오로벤질)옥시]-6-옥소피리미딘-1(6ｈ)-일]-ｎ-(2-히드록시에틸)-4-메틸벤즈아미드의결정형
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
MX2007012605A (es) * 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
CA2634133A1 (en) 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
US20100234468A1 (en) 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
WO2009024863A2 (en) 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
WO2009045488A2 (en) 2007-10-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en) 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen

Also Published As

Publication number Publication date
PT2343275E (pt) 2013-07-30
SI2343275T1 (sl) 2013-10-30
EA200501016A1 (ru) 2005-12-29
US20090281192A1 (en) 2009-11-12
DK2343275T3 (da) 2013-07-01
EP2343275A3 (fr) 2011-08-17
KR101050565B1 (ko) 2011-07-19
EG24849A (en) 2010-10-27
BRPI0316916B1 (pt) 2021-11-30
IS7947A (is) 2005-07-19
EP1572635B1 (fr) 2017-04-12
CL2016002640A1 (es) 2017-03-24
US20060135621A1 (en) 2006-06-22
EP2676952A3 (fr) 2014-02-12
TWI344952B (en) 2011-07-11
US8975442B2 (en) 2015-03-10
US8729305B2 (en) 2014-05-20
US9382200B2 (en) 2016-07-05
US20130274521A1 (en) 2013-10-17
ES2425023T3 (es) 2013-10-10
NO20052912L (no) 2005-07-19
PL377196A1 (pl) 2006-01-23
AU2003299349C1 (en) 2011-01-20
EP2679577A2 (fr) 2014-01-01
US20100048718A1 (en) 2010-02-25
AU2003299349A8 (en) 2004-07-29
HK1192222A1 (zh) 2014-08-15
EP2343275A2 (fr) 2011-07-13
AU2003299349B2 (en) 2010-06-03
CN101914044A (zh) 2010-12-15
EP2679578A2 (fr) 2014-01-01
NO20052912D0 (no) 2005-06-15
CN1751021A (zh) 2006-03-22
CN100540533C (zh) 2009-09-16
EP2679578A3 (fr) 2014-03-19
EP2679576A3 (fr) 2014-02-12
EA009592B1 (ru) 2008-02-28
US7132570B2 (en) 2006-11-07
JP4719471B2 (ja) 2011-07-06
BR0316916A (pt) 2005-10-18
CA2510096A1 (fr) 2004-07-22
NZ571235A (en) 2010-01-29
EP2343275B1 (fr) 2013-04-24
JP2006511588A (ja) 2006-04-06
CN101012189B (zh) 2013-03-13
FR2849029A1 (fr) 2004-06-25
US20100022653A1 (en) 2010-01-28
US20060241320A1 (en) 2006-10-26
AU2003299349A1 (en) 2004-07-29
AU2010212462A1 (en) 2010-09-16
US20090281193A1 (en) 2009-11-12
EP2679578B1 (fr) 2016-03-09
NO335724B1 (no) 2015-02-02
WO2004060858A1 (fr) 2004-07-22
HK1225371A1 (zh) 2017-09-08
US20100048720A1 (en) 2010-02-25
EP2676952A2 (fr) 2013-12-25
EP2679576A2 (fr) 2014-01-01
ES2627808T3 (es) 2017-07-31
IL169205A (en) 2013-11-28
EP1572635A1 (fr) 2005-09-14
CL2007002450A1 (es) 2009-01-16
UA100964C2 (ru) 2013-02-25
MY142926A (en) 2011-01-31
TW200419175A (en) 2004-10-01
CA2510096C (fr) 2011-02-22
US20140031589A1 (en) 2014-01-30
CN101654423A (zh) 2010-02-24
EP2679577A3 (fr) 2014-02-12
CN106065007A (zh) 2016-11-02
JP2011102330A (ja) 2011-05-26
CA2724305A1 (fr) 2004-07-22
CN101012189A (zh) 2007-08-08
CY1114291T1 (el) 2016-08-31
JP5497680B2 (ja) 2014-05-21
US20100048719A1 (en) 2010-02-25
MXPA05006525A (es) 2005-12-05
KR20050085847A (ko) 2005-08-29
ZA200504805B (en) 2006-07-26
NZ540733A (en) 2008-10-31
ES2575018T3 (es) 2016-06-23
BRPI0316916A8 (pt) 2015-09-22
AR042546A1 (es) 2005-06-22

Similar Documents

Publication Publication Date Title
FR2849029B1 (fr) Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
DE60311599T2 (de) Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
SE0200730L (sv) Kristallin bas av citalopram
PT100673B (pt) Processo para a preparacao de intermediarios de sertralina e compostos assim obtidos
JP5503546B2 (ja) ４，５−ジメトキシ−１−（メチルアミノメチル）−ベンゾシクロブタンの分離
PT768309E (pt) Processo para a preparacao de compostos de imidazolilo enantiomericamente puros
JP4138005B2 (ja) トレオーメチルフェニデートの分割
KR102236806B1 (ko) 거울상 이성질체 농후화된 3-아미노피페리딘의 제조 방법
BR0109507A (pt) Processo para preparação de forma i, cristalina, de carbegolina
RU97100948A (ru) Способ расщепления рацематов трамадола
KR970059155A (ko) 트라마돌의 라세미체를 분리하는 방법
WO2001083422A1 (en) Process for the separation of the cis trans diastereoisomers of tramadol
ES2307209T3 (es) Procedimiento de produccion de un enantiomero de amlodipina con una pureza optica alta.
BR102013004752A2 (pt) Processo para a transformação de medetomidina e recuperação do enantiômero indesejado
AR030938A1 (es) Proceso de obtencion de los enantiomeros de la cetamina racemica; proceso de obtencion de sales farmaceuticamente aceptables de enantiomeros de la cetamina racemica y utilizacion de las sales farmaceuticamente aceptables obtenidas por el referido proceso
AU2015349026B2 (en) Method for the production of praziquantel
AR032433A1 (es) Proceso para la preparacion de un isomero de anillo de 5 miembros 3-sustituido y compuestos intermediarios utiles en el mismo
Fang et al. First preparation of enantiomerically pure sibutramine and its major metabolite, and determination of their absolute configuration by single crystal X-ray analysis
SE8102525L (sv) Forfarande for framstellning av cyklopropankarboxylsyraester-derivat
BRPI0719205A2 (pt) Processo para a preparação de pleuromutilins
ATE402157T1 (de) Verfahren zur herstellung von mycophenolatmofetil
AR012346A1 (es) Proceso para la fabricacion de compuestos racemicos, compuestos obtenidos por dicho proceso y compuestos intermediarios
UA89037C2 (ru) Способ получения кислотно-аддитивной соли венлафаксина
Han et al. First practical synthesis of enantiomerically pure (R)-and (S)-desmethylsibutramine (DMS) and unambiguous determination of their absolute configuration by single-crystal X-ray analysis
Shi et al. Racemization of (S)-(+)-10, 11-dimethoxyaporphine and (S)-(+)-aporphine: efficient preparations of (R)-(−)-apomorphine and (R)-(−)-aporphine via a recycle process of resolution

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
CJ Change in legal form
TP Transmission of property
TP Transmission of property

Owner name: TEVA SANTE, FR

Effective date: 20140306

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20180831